NCT03739736UNKNOWNanonymous

Tuberculosis Reduction Through Expanded Anti-retroviral Therapy and Screening of Active TB Project

Sponsor

Source record

London School of Hygiene and Tropical Medicine

Phase

Source record

Phase 3

Modality

AI-normalized

combination therapy

Target

AI-normalized

Tuberculosis (TB) and HIV co-infection

Indication / condition

AI-normalized

Tuberculosis

Intervention

Source record

Combination of TB/HIV prevention activities (arm A), Combination of TB/HIV prevention activities (arm B), Standard of care (arm C)

Related intelligence directories

Indication directory: Tuberculosis Modality directory: combination therapy Target directory: Tuberculosis (TB) and HIV co-infection

Source & freshness

Source record

NCT ID

NCT03739736

Original source

ClinicalTrials.gov

Source last updated

Feb 25, 2021

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03739736

Title

Tuberculosis Reduction Through Expanded Anti-retroviral Therapy and Screening of Active TB Project

Sponsor

London School of Hygiene and Tropical Medicine

Status

UNKNOWN

Phase

Phase 3

Condition raw

Tuberculosis

Condition normalized

Tuberculosis

Modality raw

Tuberculosis

Modality normalized

combination therapy

Target raw

Tuberculosis (TB) and HIV co-infection

Target normalized

Tuberculosis (TB) and HIV co-infection

Interventions

Combination of TB/HIV prevention activities (arm A), Combination of TB/HIV prevention activities (arm B), Standard of care (arm C)

Public preview

Source record

The TREATS project aims to evaluate the impact of a combined TB/HIV intervention on TB incidence and prevalence in communities in Zambia and South Africa. It builds on the HPTN 071 (PopART) trial, focusing on population-level screening for TB and universal testing and treatment for HIV. The project seeks to provide definitive evidence for public health policy on TB control and prevention strategies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Tuberculosis Reduction Through Expanded Anti-retroviral Therapy and Screening of Active TB Project

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03739736

Status

UNKNOWN

Phase

Phase 3

Sponsor

London School of Hygiene and Tropical Medicine

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedFeb 25, 2021

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03739736

Indication

Tuberculosis

Modality

combination therapy

Target

Tuberculosis (TB) and HIV co-infection

Intervention

Combination of TB/HIV prevention activities (arm A), Combination of TB/HIV prevention activities (arm B), Standard of care (arm C)

Source record